JP5769375B2 - 老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物 - Google Patents
老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物 Download PDFInfo
- Publication number
- JP5769375B2 JP5769375B2 JP2009542246A JP2009542246A JP5769375B2 JP 5769375 B2 JP5769375 B2 JP 5769375B2 JP 2009542246 A JP2009542246 A JP 2009542246A JP 2009542246 A JP2009542246 A JP 2009542246A JP 5769375 B2 JP5769375 B2 JP 5769375B2
- Authority
- JP
- Japan
- Prior art keywords
- presbyopia
- treatment
- patients
- parasympathomimetic
- ophthalmic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
40歳から65歳までの老眼患者男女100名を、本発明の組成物を用いて処置した。なお、1ジオプトリより高い近視及び乱視を有する患者、3ジオプトリより高い遠視を有する患者、並びに角膜、レンズ、及びガラス体が混濁している者、慢性一般病理を有する者は除外されている。
老眼患者集団を4種のグループに分けた。
グループ1:他の症状を伴わない老眼(Pure presbyopics)
グループ2:遠視を伴った老眼
グループ3:斜位を伴った老眼
グループ4:緑内障を伴った老眼
以下について調整を行った。
近見及び遠見の鮮明さ
縮瞳
結膜
眼圧
眼精疲労
寛容
望ましい視覚の鮮明さが得られなかった場合、投薬量を変更し、眼球調節について検査した。
患者が縮瞳に耐えられなかった場合、角膜括約筋中360°に亘るスポットにアルゴンレーザーを照射し角膜形成を行った。レーザーの強度及びスポットのサイズは、角膜色素沈着の強度に適合させた。
結膜炎症が生じた場合は、局所処置は変更した。
眼圧が理想的でなかった場合、老眼処置の前の降圧薬剤投与を変更した。
患者が眼精疲労に陥った場合、視野訓練処置を修正した。
患者が薬剤に対する過敏症を示した場合、処置を保留にした。
患者100人を処置した:2人の患者が塩酸ピロカルピンに対する過敏症を示し(下痢及び消化不良)、2人の患者(遠視を伴った老眼)において視覚の鮮明さの望ましい改善が見られなかった。
6年間処置下にあった患者は10人で、
5年間処置下にあった患者は20人で、
4年間処置下にあった患者は30人で、
3年間処置下にあった患者は40人で、
2年間処置下にあった患者は80人で、
1年間処置下にあった患者は96人であった。
グループ1:患者の100%が老眼が矯正されるのを経験した。
Claims (2)
- 塩酸ピロカルピン及びジクロフェナクナトリウムの組み合わせを含み、
前記塩酸ピロカルピンを1%〜2%の範囲の濃度で含み、前記ジクロフェナクナトリウムを0.1%〜0.5%の範囲の量で含むことを特徴とする老眼の処置のための眼科用組成物。 - 塩酸ピロカルピン及びジクロフェナクナトリウムの組み合わせを含む老眼処置の薬剤の調製のための塩酸ピロカルピン及びジクロフェナクナトリウムを組み合わせた使用であって、
前記塩酸ピロカルピンを1%〜2%の範囲の濃度で含み、前記ジクロフェナクナトリウムを0.1%〜0.5%の範囲の量で含むことを特徴とする使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06026169.0 | 2006-12-18 | ||
EP06026169A EP1938839B1 (en) | 2006-12-18 | 2006-12-18 | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
PCT/IB2007/003780 WO2008075149A2 (en) | 2006-12-18 | 2007-12-06 | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010513454A JP2010513454A (ja) | 2010-04-30 |
JP5769375B2 true JP5769375B2 (ja) | 2015-08-26 |
Family
ID=37969963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009542246A Active JP5769375B2 (ja) | 2006-12-18 | 2007-12-06 | 老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8524758B2 (ja) |
EP (1) | EP1938839B1 (ja) |
JP (1) | JP5769375B2 (ja) |
AT (1) | ATE439863T1 (ja) |
AU (1) | AU2007335919B2 (ja) |
BR (1) | BRPI0720355B8 (ja) |
CA (1) | CA2672985C (ja) |
DE (1) | DE602006008643D1 (ja) |
DK (1) | DK1938839T3 (ja) |
ES (1) | ES2329161T3 (ja) |
MX (1) | MX2009006505A (ja) |
PT (1) | PT1938839E (ja) |
WO (1) | WO2008075149A2 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
CN104093404B (zh) | 2011-09-20 | 2016-12-07 | 阿勒根公司 | 用于治疗老花眼、轻度远视和不规则散光的组合物和方法 |
CA2874220C (en) * | 2012-02-25 | 2021-05-25 | Thrufocus Optics, Inc. | Devices and methods for improving vision using laser photomiosis |
US10744034B2 (en) * | 2012-04-25 | 2020-08-18 | Gregg S. Homer | Method for laser treatment for glaucoma |
US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
CN106061490A (zh) | 2013-10-09 | 2016-10-26 | 列奥尼达斯·A·约翰逊 | 一种治疗和预防眼部疾病症状或体征的方法及组合物 |
ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
RU2016136333A (ru) * | 2014-02-11 | 2018-03-15 | Орасис Фармасьютикалз Лтд. | Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение |
WO2016205068A1 (en) | 2015-06-18 | 2016-12-22 | Presbyopia Therapies, LLC | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
EP3500255B1 (en) * | 2016-08-19 | 2022-11-30 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
US20180104099A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Digitally controlled optical system for nonpharmacologic constriction of a pupil |
US20180104098A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | System for nonpharmacologic long-term constriction of a pupil |
US10406352B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | System for temporary nonpharmacologic constriction of the pupil |
US20180104508A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Optical system for nonpharmacologic constriction of a pupil |
US10406380B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | Method for nonpharmacologic temporary constriction of a pupil |
DK3681500T3 (da) | 2018-04-24 | 2022-06-27 | Allergan Inc | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi |
US20240000812A1 (en) * | 2020-11-13 | 2024-01-04 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating conditions of the eye |
US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001096A1 (en) * | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6263879B1 (en) | 1998-11-10 | 2001-07-24 | J. T. Lin | Treatment of presbyopia and other eye disorders using a scanning laser system |
US6258082B1 (en) | 1999-05-03 | 2001-07-10 | J. T. Lin | Refractive surgery and presbyopia correction using infrared and ultraviolet lasers |
US6540990B2 (en) * | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
US6273092B1 (en) * | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
-
2006
- 2006-12-18 EP EP06026169A patent/EP1938839B1/en active Active
- 2006-12-18 ES ES06026169T patent/ES2329161T3/es active Active
- 2006-12-18 DE DE602006008643T patent/DE602006008643D1/de active Active
- 2006-12-18 PT PT06026169T patent/PT1938839E/pt unknown
- 2006-12-18 AT AT06026169T patent/ATE439863T1/de active
- 2006-12-18 DK DK06026169T patent/DK1938839T3/da active
-
2007
- 2007-12-06 BR BRPI0720355A patent/BRPI0720355B8/pt active IP Right Grant
- 2007-12-06 CA CA2672985A patent/CA2672985C/en active Active
- 2007-12-06 AU AU2007335919A patent/AU2007335919B2/en active Active
- 2007-12-06 JP JP2009542246A patent/JP5769375B2/ja active Active
- 2007-12-06 MX MX2009006505A patent/MX2009006505A/es active IP Right Grant
- 2007-12-06 US US12/519,910 patent/US8524758B2/en active Active
- 2007-12-06 WO PCT/IB2007/003780 patent/WO2008075149A2/en active Application Filing
-
2013
- 2013-03-14 US US13/827,183 patent/US20130197047A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2672985C (en) | 2013-06-11 |
EP1938839A1 (en) | 2008-07-02 |
US20130197047A1 (en) | 2013-08-01 |
BRPI0720355A2 (pt) | 2013-12-31 |
US8524758B2 (en) | 2013-09-03 |
MX2009006505A (es) | 2009-09-18 |
AU2007335919B2 (en) | 2012-11-08 |
US20100016395A1 (en) | 2010-01-21 |
BRPI0720355B1 (pt) | 2019-02-05 |
WO2008075149A2 (en) | 2008-06-26 |
ES2329161T3 (es) | 2009-11-23 |
CA2672985A1 (en) | 2008-06-26 |
DE602006008643D1 (de) | 2009-10-01 |
PT1938839E (pt) | 2009-09-30 |
DK1938839T3 (da) | 2009-11-30 |
AU2007335919A1 (en) | 2008-06-26 |
WO2008075149A3 (en) | 2008-08-14 |
BRPI0720355B8 (pt) | 2023-01-24 |
JP2010513454A (ja) | 2010-04-30 |
EP1938839B1 (en) | 2009-08-19 |
ATE439863T1 (de) | 2009-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5769375B2 (ja) | 老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物 | |
CA2922802C (en) | Compositions and methods for the treatment of presbyopia | |
US10507245B2 (en) | Ophthalmic formulation and method for ameliorating presbyopia | |
US6273092B1 (en) | Methods for treating various eye disorders | |
US10064818B2 (en) | Compositions and methods for the treatment of presbyopia | |
US9968594B2 (en) | Compositions and methods for the treatment of presbyopia | |
WO2020252057A1 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
CA3017755A1 (en) | Compositions and methods for the treatment of presbyopia | |
US20220257593A1 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
US10052313B2 (en) | Compositions and methods for the treatment of presbyopia | |
CN116981457A (zh) | 有效预防、控制和根除老花眼的低浓度剂量的协同眼科组合物 | |
US20180140708A1 (en) | Compositions and Methods for the Treatment of Presbyopia | |
US20230210821A1 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
Taniguchi et al. | A risk-benefit assessment of drugs used in the management of glaucoma | |
KR102667598B1 (ko) | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150416 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5769375 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |